Literature DB >> 22623959

Identification of a known mutation in Notch 3 in familiar CADASIL in China.

Zhen-Xuan Tan1, Fei-Feng Li, You-Yang Qu, Ji Liu, Gui-Rong Liu, Jin Zhou, Yu-Lan Zhu, Shu-Lin Liu.   

Abstract

BACKGROUND: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited disease leading to recurrent ischemic stroke and vascular dementia. Numerous mutations in the 23 exons of the NOTCH3 gene have been reported to cause CADASIL in Caucasian populations, but the full spectrum of genetic changes leading to this disease is yet to be known and, especially, very few reports are available on CADASIL in Asian populations. METHODS AND
RESULTS: We genotyped members of a 5-generational Han Chinese family with CADASIL patients and identified an R133C mutation in the NOTCH3 gene. Clinical analysis demonstrated that the penetrance of the mutation was not complete. Five of the mutation carriers, not exposed to the known vascular risk factors, did not show any clinical feature of CADASIL, suggesting the importance of environmental factors to the development of this disease.
CONCLUSIONS: Members of a 5-generational Han Chinese family with CADASIL patients had an R133C mutation in the NOTCH3 gene but only individuals exposed to known vascular risk factors developed CADASIL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623959      PMCID: PMC3356370          DOI: 10.1371/journal.pone.0036590

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited disease with mutations in the NOTCH3 gene [1], [2], [3]. This disorder has been found in many race-ethnicities, with most reported cases coming from European Caucasian families [2], [4], [5]. To date, very few cases in Asian families have been reported [6], which however may not necessarily indicate that the disease is rare in Asia. The main clinical feature of the disease is the disfunctioning of the central nervous system (CNS), characterized by recurrent ischemic attacks or strokes, migraine, cognitive impairment, dementia and psychiatric disturbances [7]. The mean onset age is around 45 years old, ranging from 30 to 70 [2], [4], [5]. About 85% of symptomatic CADASIL patients have ischemic attacks or stroke and 22–64% show migraine, which may begin early during childhood or adolescence but mostly during the third decade [2], [4], [6]. Many CADASIL patients also show cognitive decline, dementia and psychiatric symptoms [6]. In addition to these common CNS symptoms and signs, some less frequent manifestations of the disease have also been reported, such as epilepsy, transient disturbances of consciousness, visual impairment, and hemorrhagic strokes [7], [8], [9], [10]. A large number of mutations in the 23 exons of the NOTCH3 gene have been reported to be associated with CADASIL [1], [5], [7], [11], [12], [13], [14]. However, the full spectrum of genetic changes leading to this disease is yet to be known and, especially, very few reports are available on CADASIL in Asian populations. Here, we report an R133C mutation on exon 4 of the NOTCH3 gene in members of a 5-generational Han Chinese family and describe the unusual clinical manifestations of the disease in this family.

Results

Clinical Data

The proband was a 60-year-old male (ΙΙ:5; Figure 1), whose symptoms began at the age of 47. The main clinical manifestations included mild dysarthria and left central facial and tongue paralysis. Lower jaw reflex was brisk, bilateral palm-chin reflex was brisk, bilateral gag reflex was slow, limb tendon reflexes were brisk, with the lower limbs being pronounced. Left rotation movement was clumsy, and the Romberg sign was brisk. The patient had a right hemiparesis.
Figure 1

Pedigree of a 5-generational Chinese Han family affected with CADASIL.

Squares and circles indicate males and females, respectively. Filled symbols denote affected status. Normal individuals are shown as empty symbols. Mutation carriers without evident clinical features are indicated by a circle with a vertical line in the middle (III:31, III:33, III:34, IV:30) or a square with a vertical line in the middle (IV:28). II:4 had a large area cerebral infarction but was not a CADASIL patient.

Pedigree of a 5-generational Chinese Han family affected with CADASIL.

Squares and circles indicate males and females, respectively. Filled symbols denote affected status. Normal individuals are shown as empty symbols. Mutation carriers without evident clinical features are indicated by a circle with a vertical line in the middle (III:31, III:33, III:34, IV:30) or a square with a vertical line in the middle (IV:28). II:4 had a large area cerebral infarction but was not a CADASIL patient. The MRI examination results showed long T1 and long T2 signals on the white matter around the ventricles, and punctate long T1 and long T2 signals in the brainstem (Figure 2). His intelligence score was normal. Urine routine test, blood glucose, blood lipids, liver and kidney functions, blood homocysteine levels, ECG and abdominal ultrasound results were all normal. This 5-generational family included 6 affected individuals, 72 unaffected individuals, 5 mutation carriers who did not show symptoms and one large area cerebral infarction patient (ΙΙ:4), who was not a CADASIL patient and did not have the mutation. The main clinical features of the proband and the other affected individuals in the family were summarized in Table 1.
Figure 2

Cerebral MRI examination in the CADASIL family members.

ΙΙ:5, the proband, was a 60-year-old male affected family member. ΙΙΙ:31, ΙΙΙ:32, ΙΙΙ:33 and ΙΙΙ:34 were the children of the proband (ΙΙ:5). ΙΙ:5 and ΙΙΙ:32 showed evident clinical features, but ΙΙΙ:31, ΙΙΙ:33 and ΙΙΙ:34 did not show any clinical feature, although they were all mutation carriers (see the long T1 and T2 signals). ΙΙΙ:25, ΙΙΙ:15, ΙV:25, ΙV:10 and ΙV:11 were healthy core family members. ΙΙΙ:4 is a patient with l massive cerebral infarction, who did not have the R133C mutation.

Table 1

Clinical features of the affected individuals.

PatientSexAgeOnset AgeMigraineMemoryMRI ExaminationVascular Risk FactorsOther Symptom
ΙΙ:4F6748SevereGliosis in the lefttemporal lobe, foreheadand parietallobe; massivecerebralinfarctionIneffective activity ofright limbs accompaniedby verbal clumsinessfor over 20 years;obvious memorydecline; nodysphagia or dysuria.
ΙΙ:5M6047MildLong T1 andT2 signals shownon the whitematter around theventricles; punctuatelong T1 andlong T2signals in the brainstem;CADASIL patient.SmokingUnsteady gait for2 months, gettingworse for1 week; numbnessin hands andfeet; languageunclear; ataxia;lower extremityweakness.
ΙΙΙ:32M4030+MildPunctate longT1 and longT2 signals onthe temporal lobes;bilateral basal gangliaand corona radiateand high-intensitysignals of FLAIRsequence; CADASIL patient.SmokingNumbness in handsand feet; nosymptoms ofineffective activityof the limbs,memory declineor headache.
ΙV:13M3120+MildPunctate long T1and T2 signals onright hemisphere ofcerebellum, bilateral temporallobes, bilateral basalganglia and coronaradiate, high-intensitysignals of FLAIRsequence; CADASILpatient.HypertensionDrowsinessaccompanied byparoxysmal hemicrania forover 10 years;headache during thecourse of thedisease; MMSEscore 29.
ΙΙΙ:31F41Abnormal punctate longT1 and T2signals on bilateralfrontal lobes, slightlyhigher signal intensityof lesions onFLAIR;CADASIL patient.
ΙΙΙ:34F36Abnormal punctate long T1 and long T2 signal shown on bilateral frontal lobe; CADASIL patient.
ΙΙΙ:33F36Punctate long T1and long T2signals on bilateraltemporal lobes,bilateral basal gangliaand corona radiate;CADASIL patient.

Cerebral MRI examination in the CADASIL family members.

ΙΙ:5, the proband, was a 60-year-old male affected family member. ΙΙΙ:31, ΙΙΙ:32, ΙΙΙ:33 and ΙΙΙ:34 were the children of the proband (ΙΙ:5). ΙΙ:5 and ΙΙΙ:32 showed evident clinical features, but ΙΙΙ:31, ΙΙΙ:33 and ΙΙΙ:34 did not show any clinical feature, although they were all mutation carriers (see the long T1 and T2 signals). ΙΙΙ:25, ΙΙΙ:15, ΙV:25, ΙV:10 and ΙV:11 were healthy core family members. ΙΙΙ:4 is a patient with l massive cerebral infarction, who did not have the R133C mutation.

NOTCH3 Mutation

Sanger sequencing of the amplified fragments of NOTCH3 in all affected individuals identified a single base alteration, 475C→T (Figure 3A, B), in exon 4 of the NOTCH3 gene (GI:4854) located at 19p13.2-p13.1, resulting in the substitution of Arg to Cys at codon 133 (R133C). The remainder of the coding sequence showed no other changes. Further sequence analysis revealed that all affected members in this family carried the 475C→T mutation, although 5 mutation carriers did not show symptoms. The other individuals in this family did not carry this mutation, and the mutation was not present in 100 normal controls.
Figure 3

Analysis of the DNA and protein sequences.

DNA sequence chromatogram of the R133C mutation in NOTCH3 and multiple-sequence alignment of NOTCH3 protein family. The C→T transition at position 475 resulting in the R133C mutation is located within a highly conserved region. A: DNA sequence chromatogram of the unaffected family members and ΙΙΙ:4; B: DNA sequence chromatogram of the affected family members and ΙΙΙ:31 and ΙΙΙ:33; C: multiple-sequence alignment of NOTCH3 protein family.

Analysis of the DNA and protein sequences.

DNA sequence chromatogram of the R133C mutation in NOTCH3 and multiple-sequence alignment of NOTCH3 protein family. The C→T transition at position 475 resulting in the R133C mutation is located within a highly conserved region. A: DNA sequence chromatogram of the unaffected family members and ΙΙΙ:4; B: DNA sequence chromatogram of the affected family members and ΙΙΙ:31 and ΙΙΙ:33; C: multiple-sequence alignment of NOTCH3 protein family.

Conservation of the Protein in Evolution

Comparison of NOTCH3 protein sequences from six mammalian species by multiple-sequence alignment analysis showed that the 133Arg residue was located in a highly conserved region of the protein (Figure 3C).

Discussion

In this study, we identified a mutation, 475C→T (R133C), in the NOTCH3 gene in a 5-generational Han Chinese family with CADASIL patients. This mutation co-segregated with the disease phenotype in all affected individuals except ΙΙΙ:4, who was a patient with massive cerebral infarction but not a CADASIL patient. The mutation was not present in 100 normal control subjects. Five members of the family, ?:31, ?:33, ?:34,108 ?28 and ?30, were mutation carriers but did not show any clinical feature of CADASIL. The result of multiple-sequence alignments showed that Arg133, mutation of which was previously described by Joutel [15] and Mykkanen [16], was a conserved residue, indicating its importance for normal NOTCH3 function. In this family, the penetrance rate was not 100% in the mutation carriers, but MRI examination showed that all the mutation carriers had long T1 and T2 signals within the temporal lobes and high-intensity signals of FLAIR sequence. However, ΙΙΙ:31, ΙΙΙ:33 and ΙΙΙ:34 did not show any clinical feature of CADASIL. One fact worth noting is that these three family members had not been exposed to any known vascular risk factors, such as smoking, drinking, and hypertension. On the other hand, ΙΙΙ:5, ΙΙΙ:32 and ΙV:13, who showed very evident clinical features, had obviously contacted vascular risk factors, such as smoking or hypertension. The genotype–phenotype correlation in CADASIL has not been clarified. Although some data support genotype–phenotype correlation in CADASIL [7], [13], [17], [18], the mutation found in patients of the family did not have specific effects on the expressivity of the disease. Some authors report that vascular risk factors [19], [20] or other unexplored factors may influence the phenotypic variability and lead to atypical features of the CADASIL patients, which may explain why ΙΙΙ:31, ΙΙΙ:33 and ΙΙΙ:34 did not show any clinical feature of CADASIL. However, correlations between vascular risk factors and expressivity of the disease would require larger scales of study involving many more patients and controls for a conclusion. NOTCH3 (N3) is one member of the Notch receptor superfamily, which regulates cell fate during embryonic development [21] and is predominantly expressed in vascular smooth muscle cells (VSMC) in adulthood [1], [22]. Appropriately half of identified CADASIL-related mutations are located on exons 2–4 [7], [11], which encode the extracellular domain of N3 (N3ECD) within epidermal growth factor-like (EGF-like) repeat domains [15], [23], [24]. Modular structures show that six highly conserved cysteine residues within these domains stabilize the domain [25]. Dichgans and colleagues, by blocking or facilitating disulfide bridge formation, found that multimerization of N3, at least in part, depends on disulfide bridges and unpaired cysteine residue might make CADASIL-mutated N3ECD more susceptible to multimerization in higher order complexes [26]. In summary, this study identified the 475C→T (R133C) mutation in the NOTCH3 gene in a 5-generational Han Chinese family with CADASIL. Five family members were not exposed to any vascular risk factors and they did not show any clinical feature of CADASIL. Vascular risk factors may play a vital role in the development of CADASIL.

Materials and Methods

Affected and Unaffected Individuals in the Family

We ascertained a 5-generational Chinese Han family with non-syndromic CADASIL (see Figure 1) at the Second Affiliated Hospital of Harbin Medical University, Harbin, China. Informed consent was obtained from each participant, consistent with the Declaration of Helsinki. We recorded their medical history in detail. Physical and MRI examination was carried on each of the family members. Genomic DNA was extracted from peripheral blood leukocytes using standard protocols.

DNA sequencing

Individual exons of NOTCH3 were amplified by PCR using primer pairs shown in Table S1. The PCR products were sequenced on an ABI3130 Automated Sequencer.

Multiple Sequence Alignment

From the NCBI website (http://www.ncbi.nlm.nih.gov/), the NOTCH3 protein sequence of various species were obtained and, by using the Vector NTI software, multiple-sequence alignments of NOTCH3 proteins were carried out. PCR primers and PCR product sizes for NOTCH3 sequence analysis. (DOC) Click here for additional data file.
  26 in total

1.  Diagnostic strategies in CADASIL.

Authors:  H S Markus; R J Martin; M A Simpson; Y B Dong; N Ali; A H Crosby; J F Powell
Journal:  Neurology       Date:  2002-10-22       Impact factor: 9.910

2.  Solution structure of a pair of calcium-binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders.

Authors:  A K Downing; V Knott; J M Werner; C M Cardy; I D Campbell; P A Handford
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

3.  Evaluation of DHPLC analysis in mutational scanning of Notch3, a gene with a high G-C content.

Authors:  J L Escary; M Cécillon; J Maciazek; M Lathrop; E Tournier-Lasserve; A Joutel
Journal:  Hum Mutat       Date:  2000-12       Impact factor: 4.878

4.  The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients.

Authors:  A Joutel; F Andreux; S Gaulis; V Domenga; M Cecillon; N Battail; N Piga; F Chapon; C Godfrain; E Tournier-Lasserve
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

5.  Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals.

Authors:  Poneh Adib-Samii; Glen Brice; Roswell J Martin; Hugh S Markus
Journal:  Stroke       Date:  2010-02-18       Impact factor: 7.914

6.  Detection of the founder effect in Finnish CADASIL families.

Authors:  Kati Mykkänen; Marja-Liisa Savontaus; Vesa Juvonen; Pertti Sistonen; Seppo Tuisku; Susanna Tuominen; Maila Penttinen; Johan Lundkvist; Matti Viitanen; Hannu Kalimo; Minna Pöyhönen
Journal:  Eur J Hum Genet       Date:  2004-10       Impact factor: 4.246

7.  Acute unilateral visual loss as the first symptom of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.

Authors:  Alessandra Rufa; Nicola De Stefano; Maria Teresa Dotti; Silvia Bianchi; Francesco Sicurelli; Maria Laura Stromillo; Bruno D'Aniello; Antonio Federico
Journal:  Arch Neurol       Date:  2004-04

8.  The influence of genetic and cardiovascular risk factors on the CADASIL phenotype.

Authors:  Sumeet Singhal; Steve Bevan; Tom Barrick; Philip Rich; Hugh S Markus
Journal:  Brain       Date:  2004-06-30       Impact factor: 13.501

9.  Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients.

Authors:  Christian Opherk; Nils Peters; Jürgen Herzog; Rainer Luedtke; Martin Dichgans
Journal:  Brain       Date:  2004-09-13       Impact factor: 13.501

10.  Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.

Authors:  H Chabriat; K Vahedi; M T Iba-Zizen; A Joutel; A Nibbio; T G Nagy; M O Krebs; J Julien; B Dubois; X Ducrocq
Journal:  Lancet       Date:  1995-10-07       Impact factor: 79.321

View more
  13 in total

Review 1.  Inherited neurovascular diseases affecting cerebral blood vessels and smooth muscle.

Authors:  Christine Sam; Fei-Feng Li; Shu-Lin Liu
Journal:  Metab Brain Dis       Date:  2015-04-21       Impact factor: 3.584

2.  A novel cysteine-sparing G73A mutation of NOTCH3 in a Chinese CADASIL family.

Authors:  Liyan Huang; Wei Li; Yi Li; Chaoyuan Song; Pin Wang; Hongchun Wang; Xiulian Sun
Journal:  Neurogenetics       Date:  2019-11-13       Impact factor: 2.660

3.  Combined effects of age and polymorphisms in Notch3 in the pathogenesis of cerebral infarction disease.

Authors:  Chun-Yu Zhu; Yue Wang; Qing-Xuan Zeng; Yu Qian; Huan Li; Zi-Xia Yang; Ya-Mei Yang; Qiong Zhang; Fei-Feng Li; Shu-Lin Liu
Journal:  Metab Brain Dis       Date:  2016-07-02       Impact factor: 3.584

4.  R54C Mutation of NOTCH3 Gene in the First Rungus Family with CADASIL.

Authors:  Kheng-Seang Lim; Ai-Huey Tan; Chun-Shen Lim; Kek-Heng Chua; Ping-Chin Lee; Norlisah Ramli; Giri Shan Rajahram; Fatimah Tina Hussin; Kum-Thong Wong; Meenakshi B Bhattacharjee; Ching-Ching Ng
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

5.  Characterization of SMAD3 Gene Variants for Possible Roles in Ventricular Septal Defects and Other Congenital Heart Diseases.

Authors:  Fei-Feng Li; Jing Zhou; Dan-Dan Zhao; Peng Yan; Xia Li; Ying Han; Xian-Shu Li; Gui-Yu Wang; Kai-Jiang Yu; Shu-Lin Liu
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

6.  Clinical variability of the cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy phenotype in two siblings of a large family showing the same mutation.

Authors:  Gentian Vyshka; Jera Kruja
Journal:  Int Med Case Rep J       Date:  2013-10-01

7.  Characterization of variations in IL23A and IL23R genes: possible roles in multiple sclerosis and other neuroinflammatory demyelinating diseases.

Authors:  Fei-Feng Li; Xi-Dong Zhu; Peng Yan; Mei-Hua Jin; Hui Yue; Qiong Zhang; Jin Fu; Shu-Lin Liu
Journal:  Aging (Albany NY)       Date:  2016-11-26       Impact factor: 5.682

8.  Rs2459976 in ZW10 gene associated with congenital heart diseases in Chinese Han population.

Authors:  Chao-Yu Sun; Chi Sun; Rui Cheng; Shuai Shi; Ying Han; Xue-Qi Li; Ji-Xin Zhi; Fei-Feng Li; Shu-Lin Liu
Journal:  Oncotarget       Date:  2017-12-13

9.  Characterization of Transcriptional Repressor Gene MSX1 Variations for Possible Associations with Congenital Heart Diseases.

Authors:  Fei-Feng Li; Ying Han; Shuai Shi; Xia Li; Xi-Dong Zhu; Jing Zhou; Qing-Liang Shao; Xue-Qi Li; Shu-Lin Liu
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

10.  Different effection of p.1125Val>Ala and rs11954856 in APC on Wnt signaling pathway.

Authors:  Fei-Feng Li; Zhi-Xun Zhao; Peng Yan; Song Wang; Zheng Liu; Qiong Zhang; Xiao-Ning Zhang; Chang-Hao Sun; Xi-Shan Wang; Gui-Yu Wang; Shu-Lin Liu
Journal:  Oncotarget       Date:  2017-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.